Efficacy of cardiometabolic drugs in reduction of epicardial adipose tissue: a systematic review and meta-analysis

Cardiovasc Diabetol

7 Aprile Apr 2023 10 months ago
  • Myasoedova VA, Moschetta D, Valerio V, Massaiu I, Bozzi M, Celeste F, Genovese S, Poggio P.

Epicardial adipose tissue (EAT) plays an important role in cardiometabolic risk. EAT is a modifiable risk factor and could be a potential therapeutic target for drugs that already show cardiovascular benefits. The aim of this study is to evaluate the effect of cardiometabolic drugs on EAT reduction.

Reference: Efficacy of cardiometabolic drugs in reduction of epicardial adipose tissue: a systematic review and meta-analysis.
Myasoedova VA, Parisi V, Moschetta D, Valerio V, Conte M, Massaiu I, Bozzi M, Celeste F, Leosco D, Iaccarino G, Genovese S, Poggio P. Cardiovasc Diabetol. 2023 Jan 31;22(1):23.

Go to PubMed